Details of the Drug Reposition

General Information of This Drug (ID: DM90J3J)

• Drug Name: Brilaroxazine (DM90J3J)
• Synonyms: Brilaroxazine; 1239729-06-6; X8L60BA01I; UNII-X8L60BA01I; 6-(4-(4-(2,3-Dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-one; RP-5063; 2H-1,4-Benzoxazin-3(4H)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-; 6-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-one; 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one; 2H-1,4-Benzoxazin-3(4H)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-; 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one; Brilaroxazin; BRILAROXAZINE [INN]; BRILAROXAZINE [WHO-DD]; SCHEMBL3404085; CHEMBL5095172; BDBM312188; DTXSID001136921; AKOS040741455; DB09226; MS-28159; US9604944, 15b (Example 14); HY-109112; CS-0077721; 6-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-2H-1,4-benzoxazin-3(4H)-one; 2036070-48-9
• Drug Type: Small molecule

Information on Drug Reposition of This Drug

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pulmonary arterial hypertension	DISP8ZX5	BB01.0	Phase 1	[1]
Idiopathic pulmonary fibrosis	DISZGA69	CB03.4	Phase 1	[1]

References

• [1] Clinical pipeline report, company report or official report of Reviva Pharmaceuticals